Year: 2023

Revenue was $478.0 million, a 7.9% increase over the prior yearGross margin increased 9.4% to $147.3 million, compared to Q3 2022Net loss was $102.4 million, inclusive of a $105.1 million non-cash goodwill impairment, compared to net income of $24.3 million in the comparable prior year periodAdjusted EBITDA was $36.2 million, a 46.2% increase as compared to the prior yearFull year 2023 revenue guidance raised to a range of $1,870 million to $1,880 millionFull year 2023 Adjusted EBITDA guidance raised to a range of $134 million to $137 millionATLANTA, Nov. 09, 2023 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and nine-month...

WILLIAMSBURG, Va., Nov. 09, 2023 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the third quarter ended September 30, 2023. The Company’s results include the following*:  Three Months Ended     Nine Months Ended    September 30, 2023     September 30, 2022     September 30, 2023     September 30, 2022    ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenue $ 39,181     $ 39,213     $ 131,690     $ 124,736  Net (loss) income attributable to common stockholders   (3,904 )     113       (1,353 )     21,874                         EBITDA   6,539       10,874       30,589       57,878  Hotel EBITDA   7,567       9,823       34,488       34,569                         FFO...

Conference Call and Webcast Today at 8:30 a.m. ETOCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a pediatric patient OCU400 Phase 1/2 study results suggest stabilization or improvement of Best-Corrected Visual Acuity (BCVA) or Multi-Luminance Mobility Testing (MLMT) or Low-Luminance Visual Acuity (LLVA) in treated eyes of 83% (10/12) subjects Stabilization or improvement in MLMT scores from baseline in 86% (6/7) of RHO subjects demonstrated gene-agnostic property of OCU400 modifier gene therapy and its potential benefits in broader RP and LCA subjects Ocugen’s inhaled mucosal vaccine candidate for COVID-19—OCU500—selected by National Institutes of Health (NIH)/National Institute of Allergy and Infectious...

U.S. New Drug Application for mavorixafor in WHIM syndrome accepted for Priority Review, establishing a PDUFA target action date of April 30, 2024; X4 eligible to receive Priority Review Voucher if approved Presentations of additional data from ongoing Phase 2 clinical trial of mavorixafor in chronic neutropenia expected in 4Q 2023 and 1H 2024 Pivotal, global Phase 3 trial of mavorixafor in chronic neutropenia expected to initiate in 1H 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2023 and highlighted key recent and upcoming expected milestones. “We could not be more pleased with the...

Third Quarter 2023 Highlights1Generated Revenues of $200.4 million Delivered Net Income of $10.8 million; Adjusted Net Income was $40.0 million Produced Adjusted EBITDA of $64.8 million Realized GAAP Diluted Net Income Per Share of $0.07; Adjusted Diluted Earnings Per Share was $0.28 Achieved Cash Flows from Operations of $34.4 million On August 31, 2023, paid a one-time special dividend of $1.50 per share, which represented a greater than 10% return of capital to shareholders On September 1, 2023, acquired Infinite ID, a U.S.-based digital identity solutions company for $41 million, funded with cash from the balance sheet Board of Directors approved a one-year extension of the existing share repurchase program, extending it through December 20242023 Full-Year GuidanceThe Company reiterates its full-year 2023 guidance ranges, expecting...

September YTD Net Revenue Excluding Political Flat Year-Over-YearDigital Represents 52% of September YTD 2023 Total Net Revenue and57% of September YTD 2023 Total Adjusted Operating Income PURCHASE, N.Y., Nov. 09, 2023 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare”, the “Company,” “we,” “us,” or “our”) announced today its financial results for the third quarter ended September 30, 2023. “I am pleased to share that Townsquare’s third quarter results met our previously issued guidance. In the third quarter, net revenue excluding political revenue declined -4% year-over-year (and decreased -5% year-over-year in total), and Adjusted EBITDA decreased -12% year-over-year. Our Digital Advertising segment delivered revenue and profit growth once again in the third quarter,...

– Positive interim data from Phase 1B clinical trial of SL-172154 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC) demonstrated an acceptable safety profile and encouraging anti-tumor activity that compares favorably to PLD as a monotherapy; expect to complete enrollment in this expansion cohort in the fourth quarter of 2023 – – Topline data from Phase 1A/B clinical trial of SL-172154 in relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) patients as monotherapy and in combination with Azacitidine (AZA) to be presented in a poster presentation at the American Society of Hematology (ASH) Annual Meeting; demonstrated monotherapy response and anti-leukemic activity with an acceptable safety/tolerability profile – – Completed enrollment...